XBITNasdaqPharmaceutical PreparationsFiscal year ends December 31
XBiotech Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.00−0.12 (-5.66%)
Close on Oct 19, 2026
- Market cap
- $60.98M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -65.1% | -2.0% | -28.2% | |
| Return on assets | -59.8% | -1.9% | -26.1% | |
| Current ratio | 4.64 | 81.80 | 16.01 | |
| Capex to revenue | – | 8.5% | – | |
| Diluted shares | 32M | 31M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
XBiotech generated $173.88M from operations and spent $81.08M on capital expenditure, dividends and share buybacks. 7% of that went back into the business.
Generated
$173.88M
Used
$81.08M
Capital expenditure$6.07M7%Dividends$75.00M93%Share buybacks$14.00K0%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-820.4%
×Asset turnover0.02×
×Equity multiplier1.02×
=Return on equity, FY2022-12.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -820.4% | 0.02× | 1.02× | -12.9% |
| FY2021 | -94.7% | 0.06× | 1.02× | -5.6% |
| FY2020 | -25.5% | 0.08× | 1.06× | -2.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$45.54M
- Cash generatingOperating cash flow above zero-$39.92M
- Return on assets improvedROA up on the prior year-17.0% → -22.9%
- Earnings backed by cashOperating cash flow above net income-$39.92M vs -$45.54M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose11.56 → 16.01
- No dilutionShare count did not rise30M → 30M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –